US 11,813,238 B2
Medium chain fatty acids for use in the prevention or treatment of cardiac enlargement and/or valvular heart disease
Qinghong Li, Chesterfield, MO (US); and Maurice Beaumont, Oran la Ville (CH)
Assigned to Societe des Produits Nestle S.A., Vevey (CH)
Appl. No. 16/617,668
Filed by SOCIETE DES PRODUITS NESTLE S.A., Vevey (CH)
PCT Filed May 28, 2018, PCT No. PCT/EP2018/063958
§ 371(c)(1), (2) Date Nov. 27, 2019,
PCT Pub. No. WO2018/219877, PCT Pub. Date Dec. 6, 2018.
Claims priority of provisional application 62/512,118, filed on May 29, 2017.
Prior Publication US 2020/0138762 A1, May 7, 2020
Int. Cl. A61K 31/20 (2006.01); A23L 33/12 (2016.01); A23L 33/175 (2016.01); A23L 33/16 (2016.01); A23L 33/15 (2016.01); A61P 9/10 (2006.01); A61K 31/145 (2006.01); A61K 31/198 (2006.01); A61K 31/202 (2006.01); A61K 31/355 (2006.01); A61K 33/06 (2006.01)
CPC A61K 31/20 (2013.01) [A23L 33/12 (2016.08); A23L 33/15 (2016.08); A23L 33/16 (2016.08); A23L 33/175 (2016.08); A61K 31/145 (2013.01); A61K 31/198 (2013.01); A61K 31/202 (2013.01); A61K 31/355 (2013.01); A61K 33/06 (2013.01); A61P 9/10 (2018.01); A23V 2002/00 (2013.01)] 16 Claims
 
1. A method for reduction of risk of or treatment of cardiac enlargement and/or valvular heart disease and/or a condition associated with at least one of the cardiac enlargement or the valvular heart disease in a human subject in need thereof, the method comprising:
orally administering to the human subject a composition comprising one or more medium chain fatty acids each in a form selected from the group consisting of (i) triacylglycerides in which each of the triacylglycerides comprises two or three of the medium chain fatty acids, (ii) monoacylglycerides, (iii) diacylglycerides and (iv) any mixture thereof,
the composition comprising at least 5 wt % of medium chain triglyceride (MCT), at least 0.3 wt % of docosahexaenoic acid (DHA), at least 0.4 wt % of eicosapentaenoic acid (EPA), at least 2 wt % of lysine, at least 2 wt % of methionine and cysteine combined, at least 0.15 wt % of magnesium, at least 0.9 IU/g of vitamin E, and at least 0.2 wt % of taurine, wherein the MCT comprises more than 40% of total C8 and more than 50% of total C10, and
the composition is administered simultaneously, sequentially or separately to a medicine intended to treat and/or reduce the risk of the cardiac enlargement and/or the condition associated therewith and/or a condition that increases the risk of the cardiac enlargement and/or the valvular heart disease in the human subject.